Market news

Edwards Lifesciences recently outlined its structural heart growth plan, emphasizing transcatheter valve platforms such as TAVR and TMTT, alongside the impact of updated Medicare coverage that could enable 100–200 additional U.S. centers to perform TAVR procedures. A particularly important takeaway is Edwards’ ambition to build a multibillion-dollar transcatheter mitral and tricuspid business by 2030, anchored by PASCAL, EVOQUE, and Sapien M3 technologies that aim to address complex...

Edwards Lifesciences has delivered a mixed share price story, with the stock up 18.4% over the past year but still down sharply over a 5 year span. This puts the focus squarely on what investors are paying for its future cash flows. With fresh policy news around its core heart valve franchise and a current share price of US$88.25, the key issue is whether the company’s cash generation can support where the stock trades today. Over 5 years the share price has declined 27.1%, which raises the...

An unusually high volume of out-of-the-money (OTM) put options in Edwards Lifesciences (EW) shows investors are bullish on EW stock over the next three months. Moreover, EW is below analysts' price targets.

Aristotle Capital Management, LLC, an investment management company, released its “Value Equity Fund” Q2 2026 investor letter. A copy of the letter can be downloaded here. The Fund delivered a 4.32% total return in Q2 2026, underperforming the 13.87% gain for the Russell 1000 Value Index and the 15.20% return for the S&P 500, while […]

Edwards Lifesciences (EW) recently held its annual Asia Pacific Patient Experience event, spotlighting patient and caregiver perspectives on structural heart disease. For investors, the gathering raises questions about how patient engagement connects to Edwards Lifesciences stock. See our latest analysis for Edwards Lifesciences. At a share price of $89.83, Edwards Lifesciences has seen a 6.24% 30 day share price return and a 4.72% 90 day share price return, while the 1 year total shareholder...

Edwards Lifesciences stock has delivered a 21.6% gain over the past three years, yet the valuation checks paint a less generous picture. The intrinsic value estimate from a Discounted Cash Flow (DCF) model indicates the shares are roughly fairly valued, while traditional market multiples lean expensive. Over the last three years, Edwards Lifesciences has returned 21.6%, which rewards patient holders but leaves fresh buyers needing to judge how much upside is left at today’s...

Detailed price information for Edwards Lifesciences Corp (EW-N) from The Globe and Mail including charting and trades.

Though Edwards Lifesciences has underperformed the broader market over the past year, Wall Street analysts maintain a strongly optimistic outlook on the stock’s prospects.

Baron Capital, an investment management company, released its Q2 2026 investor letter for the “Baron Health Care Fund”. A copy of the letter is available to download here. The Fund gained 11.99% during the quarter, compared with the 10.48% gain for the Russell 3000 Health Care Index and the 15.44% gain for the Russell 3000 Index. Since inception, […]

Investors need to pay close attention to EW stock based on the movements in the options market lately.

On July 23, Edwards Lifesciences Corporation (NYSE:EW) delivered second-quarter 2026 net sales of $1.74 billion, up 13.6% year over year (12.5% on a constant currency basis), surpassing Wall Street expectations of $1.70 billion. Adjusted diluted earnings per share came in at $0.78, ahead of the consensus estimate of $0.74 and up 16.4% from $0.67 a […]

Edwards Lifesciences stock sits at an interesting spot for valuation focused investors, with the Discounted Cash Flow (DCF) based intrinsic value estimate suggesting the shares are roughly in line with underlying cash flow assumptions, while the broader checks still point to a stock that does not screen as cheap and has delivered a decline over five years. Over the past 5 years, Edwards Lifesciences has delivered a total return that is down 26.4%, which raises the question of whether the...